Factors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy

Vista senzilla d'ítem
dc.contributor.authorOrtiz-Maldonado Gibson, Valentín
dc.contributor.authorRives Solà, Susana
dc.contributor.authorEspañol Rego, Marta
dc.contributor.authorAlonso Saladrigues, A.
dc.contributor.authorMontoro, Mercedes
dc.contributor.authorMagnano, Laura
dc.contributor.authorGiné Soca, Eva
dc.contributor.authorPascal i Capdevila, Mariona
dc.contributor.authorDíaz Beyà, Marina
dc.contributor.authorCastellà Castellà, Maria
dc.contributor.authorCatalà, Albert
dc.contributor.authorFaura, Anna
dc.contributor.authorRodríguez Lobato, Luis Gerardo
dc.contributor.authorOliver Caldés, Aina
dc.contributor.authorMartínez Roca, Alexandra
dc.contributor.authorRovira, Montserrat
dc.contributor.authorGonzález Navarro, Europa Azucena
dc.contributor.authorOrtega, Juan Ramón
dc.contributor.authorCid Vidal, Joan
dc.contributor.authorLozano, Miquel
dc.contributor.authorGarcía Rey, Enric
dc.contributor.authorFernández, Sara (Fernández García)
dc.contributor.authorCastro Rebollo, Pedro
dc.contributor.authorJordán García, Iolanda
dc.contributor.authorVillamor i Casas, Neus
dc.contributor.authorAymerich Gregorio, Marta
dc.contributor.authorTorrebadell Burriel, Montserrat
dc.contributor.authorDeyá, Angela
dc.contributor.authorFernández de Larrea Rodríguez, Carlos José
dc.contributor.authorBenítez-Ribas, Daniel
dc.contributor.authorTrias, Esteve
dc.contributor.authorVarea, Sara
dc.contributor.authorCalvo Rojas, Gonzalo
dc.contributor.authorEsteve Reyner, Jordi
dc.contributor.authorUrbano Ispizua, Álvaro
dc.contributor.authorJuan, Manel
dc.contributor.authorDelgado, Julio (Delgado González)
dc.date.accessioned2023-02-07T16:45:23Z
dc.date.available2023-02-07T16:45:23Z
dc.date.issued2021-12-01
dc.date.updated2023-02-07T16:45:23Z
dc.description.abstractThe prognosis of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) remains poor, particularly for those relapsing after allogeneic hema-topoietic cell transplantation (alloHCT). Novel agents such as inotuzumab ozogamicin or blinatumomab achieve increased response rates, but these are generally transient unless followed by alloHCT. Chimeric antigen receptors (CAR) targeting CD19 have shown promising results in R/R ALL, and one of these products (tisagenlecleucel) has been approved for the treatment of patients with R/R ALL up to 25 years of age.
dc.format.extent4 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec718809
dc.identifier.issn2051-1426
dc.identifier.urihttps://hdl.handle.net/2445/193208
dc.language.isoeng
dc.publisherBMJ Publishing Group
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1136/jitc-2021-003644
dc.relation.ispartofJournal for ImmunoTherapy of Cancer , 2021, vol. 9, num. 12, p. e003644
dc.relation.urihttps://doi.org/10.1136/jitc-2021-003644
dc.rightscc-by-nc (c) Ortiz-Maldonado, Valentín et al., 2021
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceArticles publicats en revistes (Medicina)
dc.subject.classificationLeucèmia limfocítica crònica
dc.subject.classificationCèl·lules canceroses
dc.subject.classificationTeràpia cel·lular
dc.subject.classificationAntígens CD
dc.subject.classificationImmunoteràpia
dc.subject.classificationReceptors cel·lulars
dc.subject.otherChronic lymphocytic leukemia
dc.subject.otherCancer cells
dc.subject.otherCellular therapy
dc.subject.otherCD antigens
dc.subject.otherImmunotheraphy
dc.subject.otherCell receptors
dc.titleFactors associated with the clinical outcome of patients with relapsed/refractory CD19+acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Miniatura
Nom:
718809.pdf
Mida:
571.93 KB
Format:
Adobe Portable Document Format
Descarregar

Col·leccions

Articles publicats en revistes (Medicina)
Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)